TGTX - TG Therapeutics Inc logo

TG Therapeutics Inc

TGTX

TG Therapeutics develops and commercializes treatments for B-cell mediated diseases, focusing on multiple sclerosis therapies like BRIUMVI. Its pipeline includes investigational drugs for relapsing MS and B-cell malignancies targeting BTK and CD47/CD19.

โš•๏ธ Healthcare NASDAQ Listed 1995 $ USD
$1,000 invested 30 years ago โ†’$1today

Score Overview

1 Year
Score
Net Growth-76.28%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth+45.67%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score7.9
Net Growth+130.47%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth+134x
Rev Trend80%
Revenue Consistencyโ€”
10 Years
Score
Net Growth+235.53%
Net Trend50%
Net Income Consistency
Rev Growth+5891x
Rev Trend50%
Revenue Consistency
20 Years
Scoreโ€”
Net Growth+12x
Net Trend40%
Net Income Consistency
Rev Growthโ€”
Rev Trend47%
Revenue Consistency
30 Years
Score
Net Growth+31x
Net Trend47%
Net Income Consistency
Rev Growth+8977x
Rev Trend43%
Revenue Consistency
All Time
Score
Net Growth+31x
Net Trend47%
Net Income Consistency
Rev Growth+8977x
Rev Trend43%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where TG Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by Net Income Growth.

Has not reached the top 50 on Net Income Growth in any year we have ranked.

  • TGTX

2007: 93.7% ยท 2021: 101.5% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-11-20
$ 63.34โ€”
1 Year2025-11-20
$ 30.45+108.01%
5 Years2021-11-19
$ 24.41+159.48%
10 Years2016-11-18
$ 5.90+10x
20 Years2006-11-20
$ 2.42K-97.39%
30 Years1996-11-20
$ 94.04K-99.93%
All Time1995-12-14
$ 77.34K-99.92%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

  • Revenue
  • Net Income
  • Cash
Year
TTM$ 897M$ 106M$ 504M
2025$ 616M$ 447M$ 141M
2024$ 329M$ 23M$ 311M
2023$ 233M$ 12M$ 217M
2022$ 2M-$ 223M$ 161M
2021$ 6M-$ 348M$ 314M
2020$ 152K-$ 279M$ 605M
2019$ 152K-$ 172M$ 140M
2018$ 152K-$ 173M$ 68M
2017$ 152.38K-$ 118M$ 84M
2016$ 152.38K-$ 78M$ 44M
2015$ 152.38K-$ 62M$ 102M
2014$ 152.38K-$ 55M$ 78M
2013$ 152.38K-$ 20M$ 45M
2012$ 19.05K-$ 18M$ 16M
2011$ 0.00-$ 853.07K$ 9M
2010$ 623.64K$ 478.67K
2009-$ 2M$ 18K
2008-$ 4M$ 106.02K
2007-$ 12M$ 649.69K
2006-$ 9M$ 3M
2005-$ 19M$ 10M
2004-$ 5M$ 5M
2003-$ 5M$ 7M
2002$ 500K-$ 1M$ 116.29K
2001$ 2M-$ 1M$ 1M
2000$ 5M-$ 5M$ 2M
1999$ 1M-$ 2M$ 3M
1998$ 3M-$ 2M$ 5M
1997$ 100K-$ 5M$ 8M
1996$ 100K-$ 3M$ 2M
TGTX - TG Therapeutics Inc logo

TG Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 152K to $ 616M and net income went from -$ 279M to $ 447M. Revenue increased in 4 of those 5 years; net income in 4.

Across TG Therapeutics Inc's full reported history, from 1996 to 2025, revenue grew from $ 100K to $ 616M and net income went from -$ 3M to $ 447M. Revenue increased in 43% of the years measured; net income in 47%.

TG Therapeutics Inc currently holds a 5-year HDB Score of 7.9 out of 10. How the HDB Score is calculated.

Membership

Continue TGTXโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,184 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$149 / year

or $19/month

Continue with Membership

30-day money-back guarantee.

Explore other companies